Bausch Health Companies Inc (BHC.TO) saw a significant jump in its stock price yesterday, thanks to strong earnings and positive guidance.
Shares of Bausch Health rose by 28.51% yesterday, closing at CA$8.43. This increase followed the company's impressive second-quarter earnings report, which not only surpassed analysts' expectations but also led to an upward revision of its 2026 revenue guidance.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.45B
52W high
$11.97
52W low
$6.10
1W change
+34.24%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 16.9% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-16.9% Upside
Current Price
C$8.43
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
86.0%
Annualized
90-Day Vol
59.3%
Annualized
Trend (90d)
+38.0%
Annualized drift
90d Mean
C$9.66
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.82 | C$6.55 – C$11.87 |
| 60 trading days | C$9.23 | C$6.07 – C$14.04 |
| 90 trading days | C$9.66 | C$5.77 – C$16.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should think about the implications of Bausch Health's strong quarterly performance and revised outlook, as it might signal a turnaround for a stock that has faced challenges this year.
Bausch Health's stock surged by 28.51% yesterday.
The company's adjusted earnings of CA$1.26 per share beat estimates by 31.25%, while revenues exceeded expectations by 7.62%.
Bull case
The impressive 40% year-over-year increase in adjusted earnings per share and the 13% rise in revenues to CA$2.85 billion reflect strong operational performance. This growth was mainly driven by the Salix and Solta Medical segments, showing a diverse revenue stream that could support future growth.
Bear case
Even with the positive earnings report, Bausch Health's stock has dropped 32.7% year-to-date, indicating ongoing challenges that investors should be aware of. The company's profit margin is still negative, and the stock's Zacks Rank suggests it may underperform in the near future.
Strong Q2 Performance
Advertisement
Bausch Health reported adjusted earnings of CA$1.26 per share, a 40% increase from last year, and revenues of CA$2.85 billion, surpassing the Zacks Consensus Estimate. This growth was largely fueled by the Salix and Solta Medical segments, with Salix revenues climbing 21% year-over-year.
Revised 2026 Guidance
Following this strong performance, Bausch Health raised its 2026 revenue outlook to between CA$10.79 billion and CA$11.04 billion, up from the previous range. This positive revision shows the company's confidence in its growth path, especially in the Salix and Solta segments.
Market Reaction and Future Outlook
The surge in Bausch Health's stock price reflects a positive market reaction to the earnings report. However, investors should stay cautious given the stock's performance this year and the broader challenges in the pharmaceutical industry. Keeping an eye on future earnings estimates will be key to evaluating the stock's potential.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
